



IBUPROFEN IR + SR IR + SR form in one Tablet

- **Indicated for** treatment of mild to moderate pain, such as headache, back pain, toothache, neuralgia, muscle and joint pain and postoperative pain, cold and flu symptoms and fever associated with common flu
- **Posology:** One tablet every 8 hours as needed. The maximum daily dose should not exceed 1200 mg

Available strength: 400mg

Fast onset of action

- Pain relief achieved within 30 minutes after administration

Long duration of pain relief

- Effective pain treatment for longer duration than standard ibuprofen on the market
- Intended both for acute and long-lasting pain

Rapid pain relief with overnight duration

Plasma levels in effective range for prolonged time vs. reference product

Innovative consumer health product



Regulatory pathway

- Legal basis: Article 10(3) hybrid application
- Reference medicinal product: Nurofen 200mg, tablets
- Bilayer tablets

Development status

- Pilot feasibility study completed by Q1 /2023

Partnership options

- Product is available for out-licensing in selected markets in Europe
- Dossier can be adjusted to markets outside Europe based on request

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.